NeoStem, Inc. Announces Licensing of Treg Patents to Strengthen Autoimmune Platform

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Sept. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, today announced the licensing of three families of patents from the University of California, San Francisco (“UCSF”). NeoStem’s worldwide exclusive license to these patents provides incremental protection for the Company’s human Regulatory T cell (“Treg”) platform, and complements the recently announced collaboration with UCSF and the laboratories of Drs. Jeffrey Bluestone and Qizhi Tang, to develop Tregs for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC